Caribou Biosciences Inc (NASDAQ:CRBU) — Market Cap & Net Worth
Market Cap & Net Worth: Caribou Biosciences Inc (CRBU)
Caribou Biosciences Inc (NASDAQ:CRBU) has a market capitalization of $140.44 Million ($140.44 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17992 globally and #4225 in its home market, demonstrating a -9.03% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Caribou Biosciences Inc's stock price $1.31 by its total outstanding shares 107207513 (107.21 Million). Also see how large is Caribou Biosciences Inc's balance sheet for a full breakdown of the balance sheet.
Caribou Biosciences Inc Market Cap History: 2021 to 2026
Caribou Biosciences Inc's market capitalization history from 2021 to 2026. Data shows change from $1.62 Billion to $140.44 Million (-38.69% CAGR). Also see CRBU operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Caribou Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #497 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1749 of 3165 |
Weight: Caribou Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Caribou Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Caribou Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Caribou Biosciences Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
15.28x
Caribou Biosciences Inc's market cap is 15.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.62 Billion | $9.60 Million | -$66.92 Million | 168.55x | N/A |
| 2022 | $673.26 Million | $13.85 Million | -$99.42 Million | 48.61x | N/A |
| 2023 | $614.30 Million | $34.48 Million | -$102.07 Million | 17.82x | N/A |
| 2024 | $170.46 Million | $9.99 Million | -$149.10 Million | 17.06x | N/A |
| 2025 | $170.46 Million | $11.16 Million | -$148.12 Million | 15.28x | N/A |
Competitor Companies of CRBU by Market Capitalization
Companies near Caribou Biosciences Inc in the global market cap rankings as of September 18, 2026. Review Caribou Biosciences Inc tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Caribou Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Caribou Biosciences Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Caribou Biosciences Inc's market cap moved from $1.62 Billion to $ 140.44 Million, with a yearly change of -38.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $140.44 Million | -17.61% |
| 2025 | $170.46 Million | 0.00% |
| 2024 | $170.46 Million | -72.25% |
| 2023 | $614.30 Million | -8.76% |
| 2022 | $673.26 Million | -58.38% |
| 2021 | $1.62 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Caribou Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $140.44 Million USD |
| MoneyControl | $140.44 Million USD |
| MarketWatch | $140.44 Million USD |
| marketcap.company | $140.44 Million USD |
| Reuters | $140.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Caribou Biosciences Inc
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD… Read more